Delving into the Latest Updates on Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) with Synapse

Overview

Basic Info

Drug Type

TIL therapy

Synonyms

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

Target

CD40L

Action

stimulants

Mechanism

CD40L stimulants(CD40 ligand stimulants), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Advanced Lung Non-Small Cell Carcinomametastatic non-small cell lung cancerRecurrent Non-Small Cell Lung Cancer

Inactive Indication-

Originator Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Active Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

Start Date11 Oct 2017

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 Clinical Results associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Translational Medicine associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Patents (Medical) associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Deals associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Phase 2	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
metastatic non-small cell lung cancer	Phase 2	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
Recurrent Non-Small Cell Lung Cancer	Phase 2	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SITC2022	Not Applicable	Non-Small Cell Lung Cancer PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	qxenxdejql(ndxinqyabt) = xgufgelede ootrjgfqul (vhingibiap, 0.02 - 30.8) View more	Positive	07 Nov 2022
SITC2022	Not Applicable	Non-Small Cell Lung Cancer PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	gzhipzdole(gsmpcxodia) = pfjiehxlgb upgdhxefmg (xxhvrgbgdl ) View more	Positive	07 Nov 2022
NCT03215810 (CTgov)	Phase 1	Adenocarcinoma \| Adenosquamous Carcinoma \| Advanced Lung Non-Small Cell Carcinoma \| Squamous Cell Carcinoma	20	Tumor-infiltrating Lymphocytes (TIL)+Nivolumab+Fludarabine+CYCLOPHOSPHAMIDE+Tumor-infiltrating Lymphocyte Therapy	okwyzoacgm(orkgkkacmt) = uuazeimveo zmhyucdqqo (kfmoxjvokk, ejoaryxiyv - nnwsuxdmds) View more	-	13 Apr 2022
ASCO2014	Phase 2	Metastatic melanoma	56	Tumor-infiltrating lymphocytes (TIL)	(lhwsykkhwq) = bztehavzxp prqdlsfsrh (fkmutrjbzn )	Positive	20 May 2014